Pharmaceutical company Promomed has agreed with four universities at SPIEF on training of specialists
At the St. Petersburg International Economic Forum (SPIEF), Promomed Group signed agreements on staff training and joint research with Mendeleev University of Chemical Technology of Russia (MUCTR), Moscow State University of Medicine and Dentistry (MSUMD), St. Petersburg State Chemical and Pharmaceutical University (SPSCPU) and Mordovia State University. The agreements were provided by the company to TASS on Friday on Friday.
The documents state that they are signed «for the purpose of cooperation in the field of training highly qualified personnel for the domestic pharmaceutical industry» and are aimed at implementing the state program «Development of the pharmaceutical and medical industry» in the context of creating additional high-tech jobs requiring highly qualified workers.
The agreement with MSUMD provides for the conclusion of contracts between the university and Promomed for paid training of students sent by the company to the university. The students will gain knowledge in medical cybernetics and pharmacy; joint research in the development of new medicines will also be conducted. MUCTR will train specialists in biotechnology and pharmaceutical biotechnology and conduct biotechnological research in cooperation with Promomed. The third party to the agreement was the Mendeleev Engineering Center, which is a subdivision of the MUCTR.
The agreement with SPSCPU, which was concluded by the Promomed’s Biokhimik plant in Saransk, includes bachelor's and master's degrees in chemical technology and biotechnology, specialist program in pharmacy, postgraduate studies in organic chemistry, pharmacology and clinical pharmacology, biotechnology, industrial pharmacy and drug production technology, pharmaceutical chemistry and pharmacognosy. In this University, joint scientific research in the field of creation of medicinal and bioactive substances will be conducted.
The agreement with the University of Mordovia provides for bachelor's and master's degrees in chemical technology and biotechnology, specialist program in pharmacy, postgraduate studies in analytical chemistry, organic chemistry, pharmacology and clinical pharmacology. Joint scientific research on the creation of medicinal and bioactive substances is also planned here.
Promomed Group is known as the manufacturer that was the first to receive approval in Russia for anti-coronavirus drug, Areplivir, on November 12, 2021. The main production site is located in Saransk (Mordovia). The company's portfolio includes more than 250 names of medicines, including products for the treatment of COVID-19 and its complications (in addition to Areplivir, these products include Esperavir, Enoparin, Radamin viro, etc.).
Source: tass.ru
